Indeed, other oncogenic mutations in the MAPK signaling pathway, such as mutations in NRAS, BRAF, or HER2 amplifications, have been identified in CRC and are implicated in tumor progression [19–23]. Here, ERBB2 is linked to colorectal carcinoma.